Abstract
The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients. Out of 20 patients, 8(40.0%) responded to the treatment. The average duration of response was 10.3 months. Response rates stratified by recurrence site were soft tissues 36.4%, bone 44.4%, liver 60.0% and lung 20.0%, respectively. No serious side effect except body weight gain, which was caused by MPA, was seen. In a 76-year-old woman with liver metastases, a marked response was obtained and has continued for more than 24 months. It was suggested that the combination of 5'-DFUR and MPA may be effective for recurrent breast cancer patients.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary*
-
Breast Neoplasms / pathology*
-
Breast Neoplasms / surgery
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / secondary*
-
Drug Administration Schedule
-
Female
-
Floxuridine / administration & dosage
-
Humans
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary
-
Mastectomy, Radical
-
Medroxyprogesterone Acetate / administration & dosage
-
Middle Aged
-
Soft Tissue Neoplasms / drug therapy*
-
Soft Tissue Neoplasms / secondary*
Substances
-
Floxuridine
-
Medroxyprogesterone Acetate
-
doxifluridine